Application of miRNA as target spot in preparation of medicine for treating non-small cell lung cancer

By targeting miR-423-5p and miR-135a-5p, inhibiting or overexpressing these drugs to bind to chemotherapy, the shortcomings in early diagnosis and treatment of non-small cell lung cancer were addressed, achieving effective inhibition of non-small cell lung cancer cells and enhancement of chemotherapy.

CN122320985APending Publication Date: 2026-07-03HUAZHONG UNIV OF SCI & TECH
0 Cites 0 Cited by

Patent Information

Application Number
CN202610372637.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-03-25
Publication Date
2026-07-03

AI Technical Summary

Technical Problem

Current technologies have low efficacy in the early diagnosis and treatment of non-small cell lung cancer, lacking effective biomarkers and therapeutic targets, resulting in limited treatment options and poor prognosis.

Method used

By using miR-423-5p and miR-135a-5p as targets, drugs for treating non-small cell lung cancer can be prepared by inhibiting or overexpressing these miRNAs and combining them with the tumor chemotherapy drugs cisplatin or carboplatin. These drugs inhibit cell growth and migration and promote apoptosis.

Benefits of technology

It significantly inhibits the growth and migration of non-small cell lung cancer cells, promotes apoptosis, and enhances the effect of chemotherapy, providing potential for early diagnosis and treatment of non-small cell lung cancer.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to application of miRNA as a target spot in preparation of a medicine for treating non-small cell lung cancer, and belongs to the technical field of biomedicine. The invention provides application of miR-423-5p or miR-135a-5p as a target spot in preparation of a medicine for treating non-small cell lung cancer, and particularly relates to application of an expression inhibitor of the miR-423-5p or an overexpression reagent of the miR-135a-5p in preparation of the medicine for treating the non-small cell lung cancer. The expression inhibitor of the miR-423-5p or the overexpression reagent of the miR-135a-5p can cause reduction of proliferation and migration capabilities of representative cells A549 and NCI-H1703 of the non-small cell lung cancer and promote cell apoptosis of the representative cells A549 and NCI-H1703, and the growth inhibition of the two cell lines can be enhanced by combining the tumor chemotherapy drug cis-platinum or carboplatin for treatment.
Need to check novelty before this filing date? Find Prior Art